Hepatitis B DNA vaccine - Oxxon Therapeutics

Drug Profile

Hepatitis B DNA vaccine - Oxxon Therapeutics

Alternative Names: Hi-8 HBV; pSG2.HBs/MVA.HBs

Latest Information Update: 17 Jul 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Oxxon Therapeutics
  • Class DNA vaccines; Hepatitis B vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Hepatitis B

Most Recent Events

  • 03 May 2006 Final results from a phase IIa clinical trial in patients with chronic hepatitis B have been added to the Viral infections therapeutic trials section
  • 03 May 2006 Oxxon has completed a phase IIa trial in hepatitis B in Poland and Serbia and Montenegro
  • 21 Dec 2005 Phase-II clinical trials in Hepatitis B treatment in Poland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top